ORLANDO, Fla. — October 10, 2025 — Leads & Copy — Nutriband Inc. has partnered with Brand Institute, Inc, to develop the worldwide commercial brand name and visual identity for its lead product, an abuse deterrent fentanyl transdermal system. The product utilizes Nutriband’s AVERSA™ abuse deterrent transdermal technology and has the development name AVERSA™ FENTANYL.
Nutriband (NASDAQ:NTRB)(NASDAQ:NTRBW) announced the agreement through its 4P Therapeutics subsidiary. AVERSA™ FENTANYL has the potential to be the world’s first abuse-deterrent opioid patch designed to deter abuse and misuse and reduce the risk of accidental exposure of opioids such as fentanyl.
Brand Institute has been leading the market for over 20 years with a 75% share of drug name approvals globally, including 87% of FDA approved names in 2024. BI has been responsible for many of the opioid chronic pain product brand names approved by FDA, and a majority of the abuse deterrent opioid product brand names approved in the United States.
Nutriband’s AVERSA™ abuse-deterrent technology is utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential including opioids and stimulants. The AVERSA™ abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
Contact Information:
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
Source: Nutriband Inc.
